Clinical Radiology
Volume 64, Issue 7 , Pages 706-713 , July 2009

Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI

  • B.J. Bryant II

      Affiliations

    • Corresponding Author InformationGuarantor and correspondent: B.J. Bryant, II, Department of Radiology, Loma Linda University Medical Center, 11234 Anderson Street, Room 2606, Loma Linda, CA 92354, USA. Tel.: +1 909 558 4000ext87814; fax: +1 909 558 0202.
    • ,
  • K. Im
    • ,
  • D.R. Broome

      Affiliations

    • D.R. Broome received one time consulting fees from GE Healthcare and Bracco Diagnostics and has received travel accomodations for a NSF Expert Panel from Bayer Healthcare.

Received 16 September 2008 ,Revised 25 March 2009 ,Accepted 21 April 2009.

References 

  1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000–1001
  2. Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging. 2007;7:130–137
  3. Todd DJ, Kagan A, Chibnik LB, et al. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007;56:3433–3441
  4. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;4:1104–1108
  5. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359–2362
  6. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis—why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586–592
  7. Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis—implications for nephrologists. Eur J Radiol. 2008;66:208–212
  8. Martin DR. Nephrogenic systemic fibrosis—a radiologist's perspective. Eur J Radiol. 2008;66:220–224
  9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  10. Markmann P, Skov L, Rossen K, et al. Clinical manifestations of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol. 2008;69:161–168
  11. Cowper SE, Robach M, Girardi M. Clinical and histological findings of nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:187–190
  12. Chesney J, Bucala R. Peripheral blood fibrocytes: mesenchymal precursors cells and the pathogenesis of fibrosis. Curr Rheumatol Rep. 2000;2:501–505
  13. Quan T, Cowpers S, Wu SP, et al. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004;35:598–606
  14. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol. 2008;66:230–234
  15. Cheng S, Abramova L, Saab G, et al. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents. MMWR. 2007;56:137–141
  16. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant. 2007;7:2425–2432
  17. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168–175
  18. Anavekar NS, Chong AH, Norris R, et al. Nephrogenic systemic fibrosis in a gadolinium-naive renal transplant recipient. Australas J Dermatol. 2008;49:44–47
  19. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27–30
  20. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21–26
  21. Marckmann P, Skov L, Rossen K, et al. Case–control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3174–3178
  22. White GW, Gibby WA, Tweedle MF. Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol. 2006;41:272–278
  23. Thomsen HS, Marckmann P. Nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:153–159
  24. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2:264–267
  25. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148–157
  26. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging. 2007;26:1198–1203
  27. Wiginton CD, Kelly B, Oto A, et al. Gadolinium based contrast exposure, nephrogenic systemic fibrosis, gadolinium detection in tissue. AJR Am J Roentgenol. 2008;190:1–9
  28. Rydahl C, Thomsen HS, Marckmann P, et al. High prevalence of nephrogenic systemic fibrosis in chronic failure patients exposed to gadodiamide, a gadolinium (Gd) containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141–144
  29. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial. 2007;20:217–219
  30. US Food and Drug Administration. Public health advisory . Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. Available at: http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm22 December 2006;
  31. Saab G, Abu-Alfa A. Are patients with moderate renal insufficiency at risk for developing nephrogenic systemic fibrosis?. Radiology. 2007;244(3):930–931
  32. US Food and Drug Administration . Information for healthcare professionals: gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MulitiHance, Omniscan, OptiMARK, ProHance). Food and Drug Administration website available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705.htmPublished June 2006. Updated 23 May 2007. [accessed 20.10.07]
  33. National Health and Nutrition Examination Survey—US 999-2004. Available at: http://www/cdc.gov/nchs/nhanes.htm[accessed 20.06.08]
  34. Saussereau E, Lacroix C, Cattaneo A, et al. Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. Forensic Sci Int. 2008;176:54–57
  35. Idee JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563–576
  36. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65–75
  37. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008;18:2164–2173
  38. Kuhn MJ, Picozzi P, Maldjian JA, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg. 2007;106:557–566
  39. Rowley HA, Scialfa G, Gao PY, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol. 2008;29:1684–1691
  40. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470
  41. Archibald G, Bartlett W, Brown A, et al. UK Consensus conference on early chronic kidney disease. Nephrol Dial Transplant. 2007;22(Suppl. 9):ix4–ix5

PII: S0009-9260(09)00140-8

doi: 10.1016/j.crad.2009.04.004

Clinical Radiology
Volume 64, Issue 7 , Pages 706-713 , July 2009

Article Tools